Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. 
Introduction
Hepatocellular carcinoma (HCC) is the third most deadly and the fifth most common malignancy worldwide, with an estimation of 600,000 new cases per year [1] . Surgical removal and liver transplantation remain the most effective therapy for HCC. Although various adjuvant approaches to treat non-resectable HCC are available, the efficacy and three-year survival rate (30-40%) are not promising [2] . Cancer stem cells (CSCs) are a newly identified subpopulation that possesses stem cell properties, and may differentiate into heterogeneous progenies of malignant cells [3] . CSCs are thought to be the cells that are least sensitive to chemotherapy or radiotherapy, and develop resistance to pharmacologic, biologic therapy, or radiotherapy [4] . These cells are probably the source for tumor metastasis and relapse. A single CD133 + cell from a colon cancer was able to form a tumor in the renal capsule of immunodeficient mice [5] . High aldehyde dehydrogenase (ALDH) activity is a common feature of stem cells, and bone marrow-derived progenitor cells with high ALDH activity displayed great engrafting potential in the mouse liver [6] . EpCAM-positive cells have been implicated as initiating/stem cells in pancreatic cancer [7] . In a recent study, we have identified a cluster of CD133 + /ALDH high cells in human HCC tissue, especially in invaded vessels, and it was demonstrated that combined staining of CD133, ALDH, EpCAM, as well as CD44 and CD90 could identify CSCs in HCC [8] .
In order to further investigate the relationship between phenotypic characteristics of CSCs and tumorigenicity, chemosensitivity, or invasion capability, we separated subpopulations of hepatoma cells according to their CSC marker expression profile. Huh-7, HLE, and HLF cell lines were enriched using APC-conjugated monoclonal antibodies against human CD133 and FITC-conjugated monoclonal antibodies against human EpCAM (Dako North America, Inc., Carpinteria, CA, USA). The staining protocol followed a report [6] with modifications. Briefly, detached cells were blocked with 20% rabbit serum, and incubated with monoclonal antibodies (CD133/EpCAM). Then, cells were suspended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) until sorting. For CD133/ALDH staining, after being labeled with APC-conjugated antibodies against CD133, cells were further incubated with Aldefluor substrate. All labeled cells were sorted in a high speed Cytopeia Influx Cell Sorter (BD Biosciences, San Jose, CA, USA). After sorting, hepatoma subpopulations were cultured in regular medium for the assays described below (see the Supplemental information for Methods not included in this part).
Formation of spheroid cores and immunofluorescent staining
FACS-enriched subpopulations of 2 Â 10 3 cells were seeded in 24-well low attachment culture plates, and cultured for 3 weeks. Then spheroid cores were counted, fixed in 4% PBS-buffered paraformaldehyde, and incubated with the primary antibodies against CD133, a-fetal protein (AFP), and proliferating cell nuclear antigen (PCNA) in combinations for double staining as described by us [8] . Stained spheroids were visualized under a Zeiss LSM510 laser scanning confocal microscope (Oberkochen, Germany).
Western blotting analysis
Total protein and the subcellular fractions of the membrane, cytosolic, and nuclear soluble proteins were extracted from FACS-isolated cell subpopulations using corresponding Extraction kits (Pierce Biotech, Rockford, IL, USA). Protein content was measured with a BCA protein assay (Pierce Biotech, Rockford IL, USA). The Western blotting assay was performed as reported previously [10] and the membranes were blotted separately with primary antibodies: monoclonal anti-E-cadherin, anti-vimentin and anti-Zeb1 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), polyclonal rabbit anti-GLI2 (Abcam), monoclonal anti-snail (Sigma), monoclonal anti-Patched/PTCH1 (Abcam). Monoclonal anti-b-actin (Sigma), anti-integrin b1 (Santa Cruz), and anti-TATA box binding protein (Abcam) were used as loading controls for cytosolic, membrane, and nuclear fractions.
Hh signaling activity by a GLI-lux reporter system
In order to determine Hh signaling activity in FACS-enriched hepatoma subpopulations, we used a GLI-lux reporter system, in which the firefly luciferase gene expression is driven by the GLI promoter [11] . 
Statistical analysis
All the experiments were performed three times with a minimum of triplicates. The data were expressed as means ± standard error of the mean (SEM), and analyzed by Student t test for difference between two groups or variance analysis, and further Newman-Keuls tests for multiple comparisons among groups. The occurrence of xenograft tumors in NOD-SCID mice in different groups was analyzed by the Chi-square test. p <0.05 was considered as statistically significant.
Results

FACS enrichment of hepatoma subpopulations
We employed well-characterized hepatoma cell lines, HepG2, Hep3B, Huh-7, HLE, HLF, and SKHep1, in which HepG2, Hep3B, and Huh-7 hepatoma cells are well-differentiated with a high level hepatic-specific gene expression. In contrast, the remaining three were poorly-differentiated with low levels of hepatic gene expression. We first separated CD133 
/EpCAM
À subpopulations for HLE and HLF. Thus, the separation of hepatoma cells according to their CSC marker profile provided subpopulations unique for the further determination of tumorigenicity, chemoresistance, and invasive capability, as well as signaling pathways affecting these critical aspects of oncogenesis and progression.
Tumorigenicity of FACS-enriched subpopulations
As shown in Fig. 2D , indicating that these cells maintained their phenotypes in vivo. Thus, it appeared that in well-differentiated hepatoma cell lines, CD133 expression is associated with higher levels of spheroid formation; however, in poorly-differentiated cell lines, CD133 expression is not essential for spheroid formation.
Enhanced chemoresistance in HLE CD133
Viable cell numbers were determined spectrophotometrically using a WST-1 reagent after exposure to cisplatin and doxorubicin, both of which are included in transarterial chemoembolization (TACE) as one of the adjuvant therapies, or sorafenib, a newly proven multikinase inhibitor targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis. As shown in Fig. 3 (Fig. 6C) . Then, we found that GLI2, a transcription factor in the Hh signaling pathway, was increased in the nuclear fraction of HLE CD133 (Fig. 6D ). After that, we transfected the Huh-7 subpopulations with a GLI-lux reporter system, and determined luciferase activity one day after transfection. It was found that luciferase activity was much higher in the Huh-7 CD133 À / EpCAM À cells than their double-positive counterparts, while cells transfected with mutated GLI-Lux did not show any luciferase activity (Fig. 6E) . Moreover, when transfected cells were treated with a Hh signaling inhibitor, cyclopamine (CPM), both cell proliferation, as determined by SWT-1 reagent, and luciferase activity were markedly inhibited by the treatment (Fig. 6E and F Hh signaling activity may be responsible for the acquisition of EMT, as well as cell proliferation, chemoresistance, and aggressive invasion capability in these cells.
Discussion
The concept of CSCs is a new paradigm of cancer biology explaining many existing basic and clinical challenges. However, controversies exist in terms of which cell markers are specific for CSCs, whether CSCs are prominent in cancer tissues, and even whether CSCs are the origin for cancer development. These controversies make the identification of CSCs in HCC more complicated. It is generally accepted that CSCs are probably the progenitor cells that undergo unknown genetic mutations, lose potential for tissue repair, but retain stem cell characteristics, such as self renewal and plasticity to differentiate into different cell types during various stages of oncogenicity and treatment [3, 13] . In this regard, it is our goal to search for CSCs in HCC tissues and to define which subpopulations in heterogeneous malignant cells represent the characteristics of CSCs in HCC. In our previous studies, we were able to co-localize CD133 + and ALDH + cells in HCC tissue, especially in the areas of connective tissues and in vessels with HCC invasion [8] . These cells were also positive for CD44 and CD90. Thus, we believe that these markers are useful in identifying CSCs in HCC tissues. However, these markers are not specific for CSCs; they are also positive for stem or progenitor cells in chronic liver injury with fibrosis/cirrhosis [8, 14] . In the present study, we separated each of the six hepatoma cell lines into subpopulations according to their CSC marker expression profile, and defined their phenotypic characteristics, such as tumorigenicity, chemoresistance, and invasive capability. More CD133 + /ALDH high or CD133 + /EpCAM + cells were separated from well-differentiated Hep3B, HepG2, and Huh-7 lines than from poorly-differentiated HLE, HLF, and SKHep1 lines. In fact, HLE, HLF, and SKHep1 cells had very low levels of CD133 positivity ( Fig. 1A and B) . We also found that CD133 
/EpCAM
À Huh-7 cells. These data are consistent with recent reports showing [15, 16] that CD133 + /ALDH high or CD133 + /EpCAM + subpopulations were more tumorigenic both in vitro and in vivo. These hepatoma cells are characterized as well-differentiated with high levels of hepatic gene expression levels, and most are AFP-positive. Thus, concerning tumorigenicity, this subpopulation has been considered as CSCs or initiating cells (TICs) with high Wnt/b-catenin signaling activity [16] . We further evaluated the chemoresistance of FACS-enriched subpopulations, and found that CD133 
À cells were more chemoresistant and invasive, which is in accordance with clinical observations that poorly-differentiated HCC is more refractory to chemotherapy and has a poor prognosis [17] and that the development of insensitivity to epithelial growth factor receptor inhibitors (erlotinib, gefitinib, and cetuximab) was a result of EMT acquisition [18] . Therefore, we hypothesized that the insensitivity to chemotherapy and more invasive capability in CD133 predisposition of cancer cells. The increased migratory activity is mediated by repression of cell to cell adhesion proteins, such as E-cadherin, and the induction of invasion-associated matrix metalloproteinase (MMP) production [19] . Currently, it is known that EMT can be induced by TGF-b1 via activation of a transcription factor, snail, by forming a complex with smad3 and smad4 [20] . Zeb1 is a zinc finger E-box transcription factor that negatively modulates the E-cadherin expression in epithelial cells through inhibition of the miRNA200 family. Zeb1 appears to be a critical factor for the initiation and dissemination of pancreatic and colorectal cancer cells [21] . The Hh signaling pathway regulates body patterning and organ development during embryo development. In adults, the Hh pathway is mainly quiescent with the exception of roles in tissue maintenance and repair, and its inappropriate reactivation has been linked to several human cancers, such as breast cancer [22] . The activation of the Hh signaling pathway occurs when Hh binds to its receptor (PTCH1), and when GLI2/3A is translocated into the nucleus to activate target genes, such as snail, bcl2, cyclin D, etc. leading to proliferation, EMT, and cell survival [23] . The activation of the Hh signaling pathway has been found in cholangiocytes and hepatocytes in models of primary biliary cirrhosis (PBC) and non-alcoholic steatohepatitis (NASH) in which the acquisition of EMT in hepatocytes and cholangiocytes contributes to the development of hepatic fibrosis [24] . To our knowledge, no previous study has explored Hh subpopulation; whereas, in poorly-differentiated hepatoma cell lines, EMT, and enhanced hedgehog signaling activity may be responsible for their chemoresistance and invasion. Our data suggest that novel molecular therapy targeting transcription factors of EMT and Hh signaling pathways could be promising in eradicating chemoresistant poorly-differentiated subpopulations in HCC. 
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